{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.85","upperLimit":"1.06","value":"0.10"},{"groupId":"OG001","lowerLimit":"-1.76","upperLimit":"0.08","value":"-0.84"},{"groupId":"OG002","lowerLimit":"-0.77","upperLimit":"0.53","value":"-0.12"},{"groupId":"OG003","lowerLimit":"-1.28","upperLimit":"0.09","value":"-0.59"},{"groupId":"OG004","lowerLimit":"-0.96","upperLimit":"0.53","value":"-0.22"},{"groupId":"OG005","lowerLimit":"-1.11","upperLimit":"0.62","value":"-0.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.28","upperLimit":"0.62","value":"-0.33"},{"groupId":"OG001","lowerLimit":"-2.24","upperLimit":"-0.40","value":"-1.32"},{"groupId":"OG002","lowerLimit":"-0.81","upperLimit":"0.52","value":"-0.14"},{"groupId":"OG003","lowerLimit":"-1.46","upperLimit":"-0.07","value":"-0.77"},{"groupId":"OG004","lowerLimit":"-1.64","upperLimit":"-0.10","value":"-0.87"},{"groupId":"OG005","lowerLimit":"-1.15","upperLimit":"0.56","value":"-0.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.38","upperLimit":"0.50","value":"-0.44"},{"groupId":"OG001","lowerLimit":"-1.86","upperLimit":"0.03","value":"-0.91"},{"groupId":"OG002","lowerLimit":"-0.66","upperLimit":"0.72","value":"0.03"},{"groupId":"OG003","lowerLimit":"-0.97","upperLimit":"0.47","value":"-0.25"},{"groupId":"OG004","lowerLimit":"-0.82","upperLimit":"0.78","value":"-0.02"},{"groupId":"OG005","lowerLimit":"-1.95","upperLimit":"-0.18","value":"-1.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.29","upperLimit":"0.59","value":"-0.35"},{"groupId":"OG001","lowerLimit":"-1.54","upperLimit":"0.40","value":"-0.57"},{"groupId":"OG002","lowerLimit":"-0.69","upperLimit":"0.73","value":"0.02"},{"groupId":"OG003","lowerLimit":"-1.20","upperLimit":"0.27","value":"-0.46"},{"groupId":"OG004","lowerLimit":"-0.74","upperLimit":"0.92","value":"0.09"},{"groupId":"OG005","lowerLimit":"-0.72","upperLimit":"1.05","value":"0.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.46","upperLimit":"1.42","value":"0.48"},{"groupId":"OG001","lowerLimit":"-1.35","upperLimit":"0.59","value":"-0.38"},{"groupId":"OG002","lowerLimit":"-0.59","upperLimit":"0.84","value":"0.12"},{"groupId":"OG003","lowerLimit":"-0.95","upperLimit":"0.52","value":"-0.22"},{"groupId":"OG004","lowerLimit":"-0.55","upperLimit":"1.15","value":"0.30"},{"groupId":"OG005","lowerLimit":"-1.21","upperLimit":"0.66","value":"-0.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.38","upperLimit":"1.50","value":"0.56"},{"groupId":"OG001","lowerLimit":"-1.23","upperLimit":"0.75","value":"-0.24"},{"groupId":"OG002","lowerLimit":"-0.70","upperLimit":"0.74","value":"0.02"},{"groupId":"OG003","lowerLimit":"-1.24","upperLimit":"0.25","value":"-0.49"},{"groupId":"OG004","lowerLimit":"-1.94","upperLimit":"-0.22","value":"-1.08"},{"groupId":"OG005","lowerLimit":"-1.10","upperLimit":"0.77","value":"-0.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.74","upperLimit":"1.31","value":"0.29"},{"groupId":"OG001","lowerLimit":"-0.22","upperLimit":"1.82","value":"0.80"},{"groupId":"OG002","lowerLimit":"-0.20","upperLimit":"1.28","value":"0.54"},{"groupId":"OG003","lowerLimit":"-0.61","upperLimit":"1.08","value":"0.23"},{"groupId":"OG004","lowerLimit":"-0.67","upperLimit":"1.16","value":"0.25"},{"groupId":"OG005","lowerLimit":"-1.02","upperLimit":"1.02","value":"-0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 10 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.15","upperLimit":"1.95","value":"0.90"},{"groupId":"OG001","lowerLimit":"-0.95","upperLimit":"1.21","value":"0.13"},{"groupId":"OG002","lowerLimit":"-0.63","upperLimit":"1.07","value":"0.22"},{"groupId":"OG003","lowerLimit":"-0.70","upperLimit":"1.07","value":"0.19"},{"groupId":"OG004","lowerLimit":"-0.43","upperLimit":"1.64","value":"0.60"},{"groupId":"OG005","lowerLimit":"-0.64","upperLimit":"1.49","value":"0.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.99","upperLimit":"1.75","value":"0.38"},{"groupId":"OG001","lowerLimit":"-1.15","upperLimit":"1.27","value":"0.06"},{"groupId":"OG002","lowerLimit":"0.06","upperLimit":"2.06","value":"1.06"},{"groupId":"OG003","lowerLimit":"-0.85","upperLimit":"1.07","value":"0.11"},{"groupId":"OG004","lowerLimit":"-3.31","upperLimit":"-0.30","value":"-1.80"},{"groupId":"OG005","lowerLimit":"-1.00","upperLimit":"1.71","value":"0.35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 14 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.66","upperLimit":"2.43","value":"0.89"},{"groupId":"OG001","lowerLimit":"-1.02","upperLimit":"2.05","value":"0.52"},{"groupId":"OG002","lowerLimit":"-0.62","upperLimit":"1.98","value":"0.68"},{"groupId":"OG003","lowerLimit":"-1.22","upperLimit":"0.98","value":"-0.12"},{"groupId":"OG004","lowerLimit":"-2.09","upperLimit":"2.88","value":"0.40"},{"groupId":"OG005","lowerLimit":"-1.75","upperLimit":"1.30","value":"-0.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.02","upperLimit":"3.14","value":"1.06"},{"groupId":"OG001","lowerLimit":"-0.98","upperLimit":"2.34","value":"0.68"},{"groupId":"OG002","lowerLimit":"-1.00","upperLimit":"1.76","value":"0.38"},{"groupId":"OG003","lowerLimit":"-1.54","upperLimit":"1.07","value":"-0.24"},{"groupId":"OG004","lowerLimit":"-3.85","upperLimit":"3.07","value":"-0.39"},{"groupId":"OG005","lowerLimit":"-1.97","upperLimit":"1.32","value":"-0.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 18 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.73","upperLimit":"1.28","value":"-1.22"},{"groupId":"OG001","lowerLimit":"-1.67","upperLimit":"1.98","value":"0.16"},{"groupId":"OG002","lowerLimit":"-2.01","upperLimit":"1.53","value":"-0.24"},{"groupId":"OG003","lowerLimit":"-1.78","upperLimit":"1.43","value":"-0.18"},{"groupId":"OG005","lowerLimit":"-2.52","upperLimit":"1.11","value":"-0.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.73","upperLimit":"-0.72","value":"-3.22"},{"groupId":"OG001","lowerLimit":"-1.40","upperLimit":"2.76","value":"0.68"},{"groupId":"OG002","lowerLimit":"-1.23","upperLimit":"2.83","value":"0.80"},{"groupId":"OG003","lowerLimit":"-2.67","upperLimit":"1.39","value":"-0.64"},{"groupId":"OG005","lowerLimit":"-1.70","upperLimit":"2.43","value":"0.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 22 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.89","upperLimit":"1.04","value":"-2.43"},{"groupId":"OG003","lowerLimit":"-4.25","upperLimit":"2.64","value":"-0.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"title":"Cycle 24 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.99","upperLimit":"1.24","value":"-0.87"},{"groupId":"OG001","lowerLimit":"-4.58","upperLimit":"-0.04","value":"-2.31"},{"groupId":"OG002","lowerLimit":"-0.84","upperLimit":"1.89","value":"0.52"},{"groupId":"OG003","lowerLimit":"-2.06","upperLimit":"0.35","value":"-0.85"},{"groupId":"OG004","lowerLimit":"-1.71","upperLimit":"1.34","value":"-0.19"},{"groupId":"OG005","lowerLimit":"-1.72","upperLimit":"1.95","value":"0.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"End of treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"description":"This test was performed in the same way as the International Shopping List Test, with the exception that, the delayed recall condition required the participant to recall the words from the list 15 30 minutes later without having the list read again. During the recognition condition, the qualified personnel read a shopping list item that may or may not have been on the original list and the participant had to respond either affirmatively (if the item was on the original list) or negatively (if it was not). Total number of correct responses made in remembering the word list after a delay was recorded. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.","dispersionType":"95% Confidence Interval","groups":[{"description":"Treatment-naïve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG000","title":"EXP-1 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG001","title":"EXP-2 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG002","title":"EXP-3 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG003","title":"EXP-4 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG004","title":"EXP-5 (Phase 2)"},{"description":"Participants with advanced ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG005","title":"EXP-6 (Phase 2)"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"PRO evaluable analysis set included all enrolled participants who received study treatment, had a baseline test assessment and at least 1 on-study test assessment. Here, 'Number Analyzed' signifies participants evaluable for specified row.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)","title":"Change From Baseline in Total Scores for International Shopping List Test-Delayed Recall (Cognitive Function Assessment) (Phase 2)","type":"SECONDARY","unitOfMeasure":"Units on a scale"}